Biocardia Inc is a biotechnology business based in the US. Biocardia Inc shares (BCDA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.14 – an increase of 15.41% over the previous week. Biocardia Inc employs 16 staff and has a trailing 12-month revenue of around $428,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.14 |
|---|---|
| 52-week range | $1.84 - $10.79 |
| 50-day moving average | $2.55 |
| 200-day moving average | $4.13 |
| Wall St. target price | $25.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.03 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.99 from 2024-11-20
| 1 week (2024-11-15) | 7.57% |
|---|---|
| 1 month (2024-10-22) | -23.46% |
| 3 months (2024-08-22) | -26.30% |
| 6 months (2024-05-22) | 543.39% |
| 1 year (2023-11-22) | 206.86% |
|---|---|
| 2 years (2022-11-22) | -92.79% |
| 3 years (2021-11-22) | 32.1 |
| 5 years (2019-11-22) | 54 |
| Revenue TTM | $428,000 |
|---|---|
| Gross profit TTM | $-7,482,000 |
| Return on assets TTM | -115.93% |
| Return on equity TTM | -703.62% |
| Profit margin | 0% |
| Book value | $-1.02 |
| Market Capitalization | $9.8 million |
TTM: trailing 12 months
We're not expecting Biocardia Inc to pay a dividend over the next 12 months.
Biocardia Inc's shares were split on a 1:15 basis on 29 May 2024 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocardia Inc shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Biocardia Inc shares which in turn could have impacted Biocardia Inc's share price.
Over the last 12 months, Biocardia Inc's shares have ranged in value from as little as $1.84 up to $10.7895. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocardia Inc's is 1.272. This would suggest that Biocardia Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioCardia, Inc. , a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.